Public lecture as part of the search for a Professor in Pathology

Abstract: Prostate cancer is the most prevalent tumor type in men and a significant public healthcare problem. The androgen receptor (AR) is the primary therapeutic target in prostate cancer. While androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSi) are effective, the disease eventually progresses to fatal castration-resistant prostate cancer (CRPC).
My lab focuses on understanding molecular changes of disease progression and resistance to AR inhibition to develop therapies aimed at preventing disease progression. We have generated a harmonized RNA sequencing atlas and related web tool (https://prostatecanceratlas.org) to interrogated transcriptional changes along disease progression. More recently, an integrated proteomic study has been concluded. Additional projects involve targeting of the AR activator TRIM24 using protein degraders to abrogate disease progression and the development of first-in-class FOXA1/2 inhibitors to disrupt the oncogenic output in different subtypes of prostate cancers.